STunning in Acute Myocardial Infarction – Beta blockers, Angiotensin converting enzyme inhibitors and Sodium/glucose cotransporter 2 inhibitors trial (STAMI-BAS)

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-511789-35-00

Enrollment

120

Registered

2024-06-27

Start date

2025-01-05

Completion date

Unknown

Last updated

2024-06-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myocardial ischemia Myocardial infarction

Brief summary

Global longitudinal strain (GLS, %) at day 7±24 hours after PCI, adjusted for baseline (day 0) GLS.

Detailed description

Left ventricular ejection fraction (LVEF), adjusted for baseline LVEF, NT-proBNP on day 7, adjusted for baseline NT-proBNP, Area under the curve of cardiac troponin-T at day 30, Area under the curve of cardiac troponin-I at day 30, Infarct size at 30 days (assessed by cardiac magnetic resonance imaging [CMRI])

Interventions

DRUGRAMIPRIL

DRUGBISOPROLOL

DRUGDAPAGLIFLOZIN

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Global longitudinal strain (GLS, %) at day 7±24 hours after PCI, adjusted for baseline (day 0) GLS.	—

Secondary

Measure	Time frame
Left ventricular ejection fraction (LVEF), adjusted for baseline LVEF, NT-proBNP on day 7, adjusted for baseline NT-proBNP, Area under the curve of cardiac troponin-T at day 30, Area under the curve of cardiac troponin-I at day 30, Infarct size at 30 days (assessed by cardiac magnetic resonance imaging [CMRI])	—

Countries

Sweden

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026